Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA)

Journal of Virological Methods

Volumn 228, Issue , 2016, Pages 84-90

  Mu, Xupeng ^a   Hu, Kebang ^a   Shen, Mohan ^b   Kong, Ning ^a   Fu, Changhao ^a   Yan, Weiqun ^a   Wei, Anhui ^a  

^a JILIN UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

HSA; Immune protection; Influenza A virus; M2e; Vaccine

Indexed keywords

GAMMA INTERFERON; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; PROTEIN ANTIBODY; PROTEIN M2; RECOMBINANT HUMAN SERUM ALBUMIN M2E FUSION PROTEIN; UNCLASSIFIED DRUG; FREUND ADJUVANT; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; RECOMBINANT VACCINE; SERUM ALBUMIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; VACCINATION; VIRAL CLEARANCE; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; CROSS PROTECTION; DISEASE OUTBREAKS; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; DISEASE OUTBREAKS; FEMALE; FREUND'S ADJUVANT; HUMANS; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; VACCINATION; VACCINES, SYNTHETIC; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 84949516465     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2015.11.014     Document Type: Article

References (37)

1. Alvarez P., Zylberman V., Ghersi G., Boado L., Palacios C., Goldbaum F., Mattion N. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice. Vaccine 2013, 31:806-812.
2. Andersson A.M., Hakansson K., Jensen B.A., Christensen D., Andersen P., Thomsen A.R., Christensen J.P. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLoS ONE 2012, 7:e46395.
3. Bakkouri K.E., Descamps F., Filette M.D., Smet A., Festjens E., Birkett A., Rooijen N.V., Verbeek S., Fiers W., Saelens X. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 2011, 186:1022-1031.
4. Black R.A., Rota P.A., Gorodkova N., Klenk H.D., Kendal A.P. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. 1993, 74:143-146.
5. Chen Z., Kadowaki S., Hagiwara Y., Yoshikawa T., Matsuo K., Kurata T. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 2000, 18:3214-3222.
6. Chuang V.T., Otagiri M. How do fatty acids cause allosteric binding of drugs to human serum albumin?. Pharm. Res. 2002, 19:1458-1464.
7. Eliasson D.G., Bakkouri K.E., Schon K., Ramne A., Festjens E., Lowenadler B., Fiers W., Saelens X., Lycke N. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26:1243-1252.
8. Feng J., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., Couch R.B., Gerhard W. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol. J. 2006, 3:102-115.
9. Fiers W., Filette M.D., Birkett A., Neirynck S., Jou W.M. A "universal" human influenza A vaccine. Virus. Res. 2004, 103:173-176.
10. Filette M.D., Fiers W., Martens W., Birkett A., Ramne A., Lowenadler B., Lycke N., Jou W.M., Saelens X. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006, 24:6597-6601.
11. Filette M.D., Jou W.M., Birkett A., Lyons K., Schultz B., Tonkyro A., Resch S., Fiers W. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337:149-161.
12. Fu T.M., Grimm K.M., Citron M.P., Freed D.C., Fan J., Keller P.M., Shiver J.W., Liang X., Joyce J.G. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27:1440-1447.
13. Hashemi H., Pouyanfard S., Bandehpour M., Noroozbabaei Z., Kazemi B., Saelens X., Mokhtari-Azad T. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS ONE 2012, 7:e45765.
14. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., Tang J., McDonald W., Song L., Evans R.K., Umlauf S., Tussey L., Powell T.J. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
15. Ito T., Gorman O.T., Kawaoka Y., Bean W.J., Webster R.G. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol. 1991, 65:5491-5498.
16. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine basedon the extracellular domain of M2: weak protection mediated via antibody dependent NK cell activity. J. Immunol. 2004, 172:5598-5605.
17. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control Release 2008, 132:171-183.
18. Laemmli U.K. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
19. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633.
20. Lee Y.N., Kim M.C., Lee Y.T., Hwang H.S., Cho M.K., Lee J.S., Ko E.J., Kwon Y.M., Kanq S.M. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection. Vaccine 2014, 21:485-492.
21. Liang S., Mozdzanowska K., Palladino G., Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 1994, 152:1653-1661.
22. Liu W., Li H., Chen Y.H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol. Med. Microbiol. 2003, 35:141-146.
23. Liu X., Guo J., Han S., Yao L., Chen A., Yang Q., Bo H., Xu P., Yin J., Zhang Z. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. Vaccine 2012, 30:6527-6533.
24. Markine-Goriaynoff D., Coutelier J.P. Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J. Virol. 2002, 76:432-435.
25. Mozdzanowska K., Zharikova D., Cudic M., Otvos L., Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol. J. 2007, 4:118.
26. Mu X.P., Wei A.H., Shen M.H., Yan W.Q. Secretory expression of HSA/M2e fusion protein in Pichia pastoris. Chin. J. Gerontol. 2010, 30:617-619.
27. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999, 5:1157-1163.
28. Patel A., Tran K., Gray M., Li Y., Ao Z., Yao X., Kobasa D., Kobinger G.P. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 2009, 27:3083-3089.
29. Patel A., Graya M., Li Y., Kobasa D., Yao X., Kobinger G.P. Co-administration of certain DNA vaccine combinations expressing different. H5N1 influenza virus antigens can be beneficial or detrimental to immune protection. Vaccine 2012, 30:626-636.
30. Quan F.S., Vunnava A., Compans R.W., Kang S.M. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS ONE 2010, 5:e9161.
31. Ramos E.L., Mitcham J.L., Koller T.D., Bonavia A., Usner D.W., Balaratnam G., Fredlund P., Swiderek K.M. Efficacy and safety of treatment with an anti-M2e monoclonal antibody in experimental human influenza. J. Infect. Dis. 2015, 211:1038-1044.
32. Reid A.H., Fanning T.G., Janczewski T.A., McCall S., Taubenberger J.K. Characterization of the 1918 "Spanish" influenza virus matrix gene segment. J. Virol. 2002, 76:10717-10723.
33. Schotsaert M., Filette M.D., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev. Vaccines 2009, 8:499-508.
34. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 1990, 64:1375-1377.
35. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 1988, 62:2762-2772.
36. Zhao G., Du L., Xiao W., Sun S., Lin Y., Chen M., Kou Z., He Y., Lustiqman S., Jiang S., Zheng B.J., Zhou Y. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 2010, 28:7233-7240.
37. Zhong W., Reed C., Blair P.J., Katz J.M., Hancock K. Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A (H1N1) virus in humans. J. Infect. Dis. 2014, 209:986-994.